Clinical development and management of adverse events associated with FGFR inhibitors

Approved fibroblast growth factor receptor (FGFR) inhibitors include erdafitinib, pemigatinib, and futibatinib. We review the most common toxicities associated with FGFR inhibitors and provide practical advice regarding their management. Hyperphosphatemia can be managed with careful monitoring, dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Vivek, Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591034/
https://www.ncbi.nlm.nih.gov/pubmed/37757826
http://dx.doi.org/10.1016/j.xcrm.2023.101204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591034/
https://www.ncbi.nlm.nih.gov/pubmed/37757826
http://dx.doi.org/10.1016/j.xcrm.2023.101204

Ejemplares similares